Loading stock data…
PACB
$1.37-0.01 (-0.72%)
After Hours$1.37+0.00 (+0.00%)· Last close Jun 9
Pacific Biosciences of California, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Pacific Biosciences of California, Inc. in the Healthcare sector is trading at $1.37. Wall Street consensus targets $2.46 (6 analysts), implying a +79.4% move over the next 12 months. The stock is currently near its 52-week low of $1.09, remaining 18.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +79.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$1.37
Potential Downside
0%
Whystock Fair Value$1.37
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technol...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-5434.32%
Volume
Today's trading volume
3.76M
Recent News
How The Pacific Biosciences (PACB) Investment Narrative Is Evolving Without New Analyst Targets
Pacific Biosciences of California is currently working with the same analyst price targets investors have seen recently, with no changes reported. With no fresh analyst commentary accompanying this update, the market narrative around those targets is being shaped largely by existing views and new data points from the company itself. In this article, you will see how to track these steady targets, how to read between the lines when commentary is quiet, and how to stay on top of the ways the...
Here's Why You Should Add PacBio Stock to Your Portfolio Now
PACB's growth is supported by HiFi sequencing advances and product momentum, though funding pressures weigh on instrument demand.
Q1 Earnings Highs And Lows: PacBio (NASDAQ:PACB) Vs The Rest Of The Life Sciences Tools & Services Stocks
Looking back on life sciences tools & services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including PacBio (NASDAQ:PACB) and its peers.
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.
3 Russell 2000 Stocks Walking a Fine Line
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.